Information About Trasylol (Aprotinin) Being Linked to Tens of Thousands of Deaths

Share Article

The FDA ordered Bayer to remove Trasylol (aprotinin) from the market after studies linked Trasylol to tens of thousands of deaths. A study looked at more than 78,000 patients from January 2003 to January 2006 and concluded that Trasylol users have a 64% higher death risk than those that took an alternative drug. The increased death risk was due to Trasylol dangerous side effects including kidney failure, heart attack, and stroke. provides detailed information, helpful links and the CBS 60 Minutes Video Segment about Trasylol.

Bernstein Liebhard & Lifshitz, LLP, a law firm named to the prestigious National Law Journal's Plaintiffs' Hot List for the past five years, announced today that it has added content to its Consumer Resource Center website that provides consumers with information about an FDA recall of Trasylol, Consumer Injury Lawyers | Trasylol (Aprotinin) Dangerous Drug Side Effects Information.

About Trasylol
Trasylol was used by surgeons to prevent blood loss during heart surgery, including coronary artery bypass graft surgery (CABG) in particular to reduce blood loss and the need for blood transfusions. Manufactured by Bayer, Trasylol received FDA approval in 1993. Trasylol, also known by its generic name Aprotinin, is a popular drug that has been administrated to more than one million patients in over 60 countries. In November 2007, Bayer stopped producing Trasylol because it was linked to several severe side effects including kidney failure, heart attack and stroke.

Trasylol FDA Warnings & Recall
In September 2006, the FDA ordered Bayer to add a box warning to Trasylol's label about kidney failure and death risk. In November 2007, the FDA ordered Bayer to remove Trasylol from the market after studies linked Trasylol use to tens of thousands of deaths.

Trasylol and Kidney Failure
In 2006, researchers at the Ischemic Research and Education Foundation in San Bruno, CA conducted a study of Trasylol. The study revealed that Trasylol users were twice as likely to suffer kidney failure compared to other patients. Kidney failure is a serious and life threatening condition. In severe cases, kidney dialysis may be required, which is the removal of waste and fluids from the kidneys when the kidneys stop functioning. The researchers calculated that 10,000 Trasylol users are currently on dialysis because of kidney failure.

Trasylol (aprotinin) prevents blood loss by destroying anti-blood clotting enzymes. This may cause blood clots in the blood vessels that lead to the kidneys. These blood clots stop hazardous wastes and fluids from reaching the kidneys and can lead to kidney failure.

Trasylol kidney failure symptoms may include:

  •     Stomach or intestinal bleeding
  •     Fluid retention
  •     Reduced urine output
  •     Fatigue
  •     Loss of appetite
  •     Seizures

Trasylol Patients and Strokes
A January 2006 study published in the New England Journal of Medicine found that Trasylol users have a 181% greater chance of suffering a stroke compared to non-Trasylol patients. An Ischemic Research and Education Foundation's study concluded that the stroke risk for Trasylol users was tripled compared to other patients. These two studies are inconsistent with Trasylol's label that places the stroke risk at two times less than the stroke risk in a control group.

How Does Trasylol Cause a Stroke? Most strokes are ischemic strokes, which occur when a blood vessel is blocked and stops blood flow to the brain. Trasylol causes blood clots by destroying the plasmin enzyme that prevents bloods clots. Therefore, Trasylol users have a greater blood clotting risk and an increased stroke risk.

Trasylol stroke symptoms may include sudden:

  •     Numbness or weakness of the face, arm or leg (especially on one side of the body);
  •     Confusion, trouble speaking or understanding speech
  •     Vision loss
  •     Trouble walking, dizziness, loss of balance or coordination
  •     Severe headaches with no known cause

Trasylol and Heart Attack Risk
Trasylol users have a high risk of suffering a heart attack. A 2006 study found that Trasylol users have a 50 percent increased heart attack risk compared to patients taking a generic Trasylol alternative. There was no increased heart attack risk evident in the Trasylol generic alternatives Aminocaproic acid or Tranexamic acid.

Trasylol heart attack symptoms may include:

  •     Chest pain (most common symptom typically described as a tight, pressured, or squeezing sensation in the chest area)
  •     weakness
  •     sweating
  •     nausea
  •     vomiting
  •     arrhythmias (abnormal heart rhythm).

Health Care Costs and Trasylol Alternatives
Aminocaproic acid and Tranexamic acid are two generic alternatives that perform the same blood clotting function as Trasylol. Studies reveal that the generic alternatives do not pose any increased risk for dangerous side effects. The Ischemic Foundation's study revealed that using Trasylol alternatives instead of Trasylol could prevent more than 11,000 kidney problems, save over a billion dollars in healthcare, and reduce worldwide drug costs by $250 million. Union health and welfare funds and other private insured plans may have the legal right to be reimbursed for monies paid for Trasylol. Bernstein Liebhard represents union health and welfare plans in such lawsuits.

Contact Bernstein Liebhard & Lifshitz, LLP

Trasylol lawsuits are being filed around the country on behalf of Trasylol victims and their families.

If you or a loved one underwent coronary bypass surgery prior to Trasylol's recall in 2007 and suffered kidney failure, heart attacks or a stroke, you may have been injured by Trasylol. Trasylol users may file a lawsuit against Bayer, Trasylol's manufacturer, for injuries suffered from Trasylol's dangerous side effects, including kidney failure, stroke, and heart attack. If you or a loved one suffered these injuries you may file a lawsuit seeking compensation for medical bills; lost income; pain and suffering; mental anguish and other losses.

Contact Bernstein Liebhard's experienced Trasylol attorneys for a confidential and free case evaluation. You can reach us at (877) 779-1414 or by visiting | Trasylol Dangerous Product Alert and completing the online form.

Bernstein Liebhard & Lifshitz, LLP is a nationally recognized law firm located in New York City that exclusively represents injured plainiffs in a variety of individual and class actions. We have been ranked among the top plaintiffs law firms in the coutry by the National Law Journal for the past five years--an honor achieved by only one other law firm in the the United States. Our experienced Levaquin trial attorneys are standing by ready to review your case. We represent our injured clients on a contigency fee basis, meaning that we advance all costs and do not collect any attorneys fees unless we are successful.

Attorney Advertising. Prior results do not guarantee a similar outcome.


Share article on social media or email:

View article via:

Pdf Print

Contact Author

Visit website